Discovery, characterization, and clinical development of the glucagon-like peptides

The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the histo...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2017-12, Vol.127 (12), p.4217-4227
Main Authors: Drucker, Daniel J, Habener, Joel F, Holst, Jens Juul
Format: Article
Language:English
Subjects:
Amino acids
Analysis
Animals
Biology
Biomedical research
Care and treatment
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Drug Discovery
Endocrinology
Gastrointestinal surgery
Genes
Glucagon
Glucagon-Like Peptide 1 - pharmacology
Glucagon-Like Peptide 2 - pharmacology
Glucagon-Like Peptide-1 Receptor - agonists
Glucagon-Like Peptide-1 Receptor - physiology
Harrington Prize
Hormones
Humans
Insulin
Intestine
Laboratories
Malabsorption syndromes
Medical innovations
Mucosa
Obesity
Peptides
Polypeptides
Reviews
Rodents
Short bowel syndrome
Short Bowel Syndrome - drug therapy
Structure-Activity Relationship
Studies
Thyroid gland
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance.
ISSN:0021-9738
1558-8238
DOI:10.1172/jci97233